Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study.

HBV integration hepatocellular carcinoma minimal residual disease recurrence monitoring urine cell-free DNA

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
25 Apr 2023
Historique:
received: 13 02 2023
revised: 02 03 2023
accepted: 21 03 2023
medline: 13 5 2023
pubmed: 13 5 2023
entrez: 13 5 2023
Statut: epublish

Résumé

Hepatitis B virus (HBV)-host junction sequences (HBV-JSs) has been detected in the urine of patients with HBV infection. This study evaluated HBV-JSs as a marker of minimum residual disease (MRD) and tumor recurrence after treatment in HBV-hepatocellular carcinoma (HCC) patients. Archived serial urine DNA from two HBV-HCC with recurrence as confirmed by MRI and four HBV-related cirrhosis (LC) patients were used. Urinary HBV-JSs were identified by an HBV-targeted NGS assay. Quantitative junction-specific PCR assays were developed to investigate dynamic changes of the most abundant urinary HBV-JS. Abundant urinary HBV-JSs were identified in two cases of tumor recurrence. In case 1, a 78-year-old female with HBV- HCC underwent a follow-up MRI following microwave ablation. While MRI results were variable, the unique HBV-JS DNA, HBV-Chr17, steadily increased from initial diagnosis to HCC recurrence. In case 2, a 74-year-old male with HBV-HCC contained two HBV-JS DNA, HBV-Chr11 and HBV-

Identifiants

pubmed: 37174929
pii: diagnostics13091537
doi: 10.3390/diagnostics13091537
pmc: PMC10177231
pii:
doi:

Types de publication

Case Reports

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : R01 CA202769
Pays : United States
Organisme : NCI NIH HHS
ID : R44 CA165312
Pays : United States
Organisme : NCI NIH HHS
ID : RO1 CA202769
Pays : United States

Références

Cancer Biomark. 2005;1(2-3):177-82
pubmed: 17192038
Eur J Cancer. 2022 Dec;177:175-185
pubmed: 36368251
J Gastroenterol Hepatol. 2007 Nov;22(11):1929-35
pubmed: 17914972
J Mol Diagn. 2011 Sep;13(5):474-84
pubmed: 21726666
Clin Mol Hepatol. 2022 Apr;28(2):276-331
pubmed: 35430783
World J Gastroenterol. 2014 Apr 21;20(15):4160-6
pubmed: 24764654
Front Oncol. 2021 Dec 17;11:803133
pubmed: 34976841
Genome Res. 2013 Sep;23(9):1422-33
pubmed: 23788652
Clin Mol Hepatol. 2022 Oct;28(4):739-753
pubmed: 35468711
Cancer Chemother Pharmacol. 1989;23 Suppl:S1-3
pubmed: 2538253
Hepatology. 2020 Dec;72(6):2063-2076
pubmed: 32171027
Liver Cancer. 2015 Mar;4(2):106-14
pubmed: 26697413
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Biomed Res Int. 2013;2013:310427
pubmed: 24455683
Ann Surg Oncol. 2009 Jun;16(6):1560-71
pubmed: 19259739
Cells. 2021 May 23;10(6):
pubmed: 34071075
Ann N Y Acad Sci. 2008 Aug;1137:197-206
pubmed: 18837947
Mol Clin Oncol. 2013 Jul;1(4):593-598
pubmed: 24649215
Clin Liver Dis. 2006 May;10(2):339-51, ix
pubmed: 16971265
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Ann Surg. 2006 Feb;243(2):229-35
pubmed: 16432356
Br J Cancer. 2022 Jun;126(10):1432-1438
pubmed: 35046521
PLoS One. 2016 Feb 22;11(2):e0148493
pubmed: 26901762
Cancer Res. 1986 Nov;46(11):5767-71
pubmed: 3019535
Korean J Radiol. 2005 Jul-Sep;6(3):134-5
pubmed: 16145287
Radiology. 2008 May;247(2):311-30
pubmed: 18430871
Clin Mol Hepatol. 2022 Oct;28(4):583-705
pubmed: 36263666
Surgeon. 2012 Oct;10(5):260-6
pubmed: 22959159
Nat Rev Clin Oncol. 2017 Mar;14(3):155-167
pubmed: 27644321
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339
pubmed: 35403533
Acta Med Okayama. 2005 Oct;59(5):217-24
pubmed: 16286955
Nat Genet. 2012 May 27;44(7):765-9
pubmed: 22634754
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
N Engl J Med. 2008 Nov 6;359(19):2045-7
pubmed: 18923166
Hepatology. 2001 Dec;34(6):1225-41
pubmed: 11732013
Nat Genet. 2012 May 27;44(7):760-4
pubmed: 22634756
Gut. 2016 Apr;65(4):625-34
pubmed: 25654990
Hepatol Commun. 2021 Oct;5(10):1649-1659
pubmed: 34558837
Hepatoma Res. 2017;3:105-111
pubmed: 28795155
Ann N Y Acad Sci. 2008 Aug;1137:82-91
pubmed: 18837929
Diagnostics (Basel). 2021 Aug 14;11(8):
pubmed: 34441409
Clin Mol Hepatol. 2022 Apr;28(2):207-218
pubmed: 34814239

Auteurs

Selena Y Lin (SY)

JBS Science Inc., Doylestown, PA 18901, USA.

Dina Halegoua-DeMarzio (D)

Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Peter Block (P)

Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Yu-Lan Kao (YL)

Department of Translational Science, Baruch S. Blumberg Institute, Doylestown, PA 18901, USA.

Jesse Civan (J)

Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Fwu-Shan Shieh (FS)

JBS Science Inc., Doylestown, PA 18901, USA.

Wei Song (W)

JBS Science Inc., Doylestown, PA 18901, USA.

Hie-Won Hann (HW)

Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Ying-Hsiu Su (YH)

Department of Translational Science, Baruch S. Blumberg Institute, Doylestown, PA 18901, USA.

Classifications MeSH